Literature DB >> 277718

Transient carcinoembryonic antigen (CEA) elevations following resection of colorectal cancer: a limitation in the use of serial CEA levels as an indicator for second-look surgery.

R A Rittgers, G Steele, N Zamcheck, M S Loewenstein, P H Sugarbaker, R J Mayer, J J Lokich, J Maltz, R E Wilso.   

Abstract

In a previous study, other investigators recommended second-look surgery for colorectal cancer primarily on the basis of plasma carcinoembryonic antigen (CEA) rises and prepared a nomogram for ready recognition of these "significant" increases. We found 25 patients whose CEA levels met the recommended criteria for significance; however, in 9 of these patients the rises were transient. Eight had no clinical evidence of recurrent cancer and they might have had negative second-look surgery had this been done because of CEA rises alone. The use of the CEA nomogram merely eliminated laboratory variation as a cause of the CEA rise. It did not, however, rule out biologic causes of CEA rises, other than that of cancer, especially benign liver disease. We were unable to differentiate benign from malignant rises on the basis of CEA changes alone. Preoperative CEA values helped to separate the two rises. Transient rises usually began earlier. Malignant CEA rises were more likely to be exponential. The rate of rise alone did not discriminate between the two rises. Thus, although serial CEA levels were helpful in making the decision for reexploration, they did not substitute for complete clinical assessment.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 277718

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Symposium: The management of recurrent colorectal cancer.

Authors:  F F Attiyeh; H Ellis; M Killingback; G D Oates; P F Schofield; H J Staab; G Steele; P H Sugarbaker
Journal:  Int J Colorectal Dis       Date:  1986-07       Impact factor: 2.571

2.  Carcinoembryonic antigen and recurrent colorectal cancer.

Authors:  J Northover
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

3.  A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma.

Authors:  J Boey; H C Cheung; C K Lai; J Wong
Journal:  World J Surg       Date:  1984-06       Impact factor: 3.352

4.  The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies.

Authors:  H J Staab; T Brümmendorf; A Hornung; F A Anderer; G Kieninger
Journal:  Klin Wochenschr       Date:  1985-02-04

Review 5.  Clinical perspective of human colorectal cancer metastasis.

Authors:  D A August; R T Ottow; P H Sugarbaker
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

6.  Serum CEA testing in the post-operative surveillance of colorectal carcinoma.

Authors:  K R Hine; P W Dykes
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

7.  Patients at risk for peritoneal surface malignancy of colorectal cancer origin: the role of second look laparotomy.

Authors:  Bldm Brücher; A Stojadinovic; A Bilchik; M Protic; M Daumer; A Nissan; A Itzhak
Journal:  J Cancer       Date:  2013-03-15       Impact factor: 4.207

8.  Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.

Authors:  J M Bhatavdekar; D D Patel; D D Giri; N H Karelia; H H Vora; N Ghosh; N G Shah; S N Trivedi; D B Balar
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

9.  Growth of human colonic adenocarcinoma and development of serum CEA in in athymic mice. I: Strict correlation of tumour size and mass with serum CEA concentration during logarithmic growth.

Authors:  H J Staab; F A Anderer
Journal:  Br J Cancer       Date:  1982-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.